This complements our observation of a protective effect of increased astrocyte TNS3 levels in APOE*4+ subjects and may corroborate the emerging consensus to reduce APOE levels in APOE*4+ subjects to counter AD risk3. This evidence concerns the gene APOE and Alzheimer disease.